New hires expected to reinforce the company's clinical and digital trial expertise.
ObvioHealth, a virtual research organization (VRO), has announced the appointmet of John Cassidy as chief financial officer and Florence Mowlem as VP of science. Previously, Cassidy served as the global head of product and commercial for eClinical at LabCorp while Mowlem joins ObvioHealth after working for Medable, where she led a team driving the implementation of electronic clinical outcomes assessments (eCOAs).
"ObvioHealth has a unique model blending clinical expertise with a robust platform to deliver stronger evidence and accelerated timelines for drug development," said Cassidy, in a company press release. "It is the perfect time to join this experienced team to help bring the business to a new level of growth."
Reference: ObvioHealth Strengthens Leadership Team with Key Industry Appointments. PR Newswire. October 17, 2023. Accessed October 19, 2023. https://www.prnewswire.com/news-releases/obviohealth-strengthens-leadership-team-with-key-industry-appointments-301956006.html
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.